Shortages led to a 2.7% decrease in use of two common platinum-based chemotherapies: cisplatin and carboplatin.
The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancers.
A conversation with Stacy Loeb, MD Professor of Urology and Population Health at NYU Langone Health and the Manhattan VA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback